Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01588457
Other study ID # HSC20110361H
Secondary ID 1P30MH086045-01A
Status Completed
Phase Phase 4
First received
Last updated
Start date June 2011
Est. completion date December 2016

Study information

Verified date August 2020
Source The University of Texas Health Science Center at San Antonio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare which of the two mood stabilizers (drugs that help to steady/stabilize mood in patients with bipolar disorder (BD)), lithium and divalproex, is more effective in patients with bipolar disorder over 26 weeks. The study will also compare if lithium or divalproex used alone versus lithium or divalproex used with quetiapine versus lithium or divalproex used with lamotrigine is more effective when symptoms of depression develop.


Description:

This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers (MS), lithium [Li] or divalproex [Div]. Those who develop protocol defined depression will then be randomized to a MS alone, MS + quetiapine [QTP] or MS + lamotrigine [LTG]. A SMART strategy employs a rule for adding new treatments based on each patient's current illness state and response during the trial, mimicking the adaptive nature of treatment selection which occurs in clinical settings, but in a controlled way which allows application of causal inference. By using early indices of response to dynamically alter treatment decisions to improve outcome, SMART eliminates unmeasured confounders associated with treatment decisions that are not randomized, as occurs in data mining exercises and in other non-randomized decisions in studies which randomize one variable at baseline. This sequential adaptive design represents a methodological innovation in bipolar trial history which will have particular implications for effectiveness studies.

Specific Aim A.1: Assess the feasibility of a SMART design in the conduct of an effectiveness study over 26 weeks in patients with BD (bipolar disorder).

Aim A.2 Compare the effectiveness of Li to Div as a primary component of treatment for BD over 26 weeks.

Aim A.3: Assess the effectiveness of MS + QTP and MS + LTG versus MS in subjects who develop depression.

A4. Exploratory Aims: 1.Determine the effects of ethnicity, language facility, education and stress as moderators of treatment outcomes; 2. Explore the use of novel statistical methodologies to more informatively characterize illness trajectories in response to the interventions. In the aggregate these aims also will clarify whether the SMART confirms results provided by traditional, single point randomized controlled trials (RCTs).


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- DSM-IV TR (Diagnostic and Statistical Manual Edition IV Text Revision) diagnosis BD I or II as assessed by MINI PLUS (Mini International Neuropsychiatric Interview PLUS)

- Male or female = 18 years old

- Currently symptomatic with a CGI-BP-S =3 for mania/hypomania &/or depression for = 2 weeks

- One of the following indicators of recent active illness: a depressive or manic or hypomanic or mixed episode in the past 12 months

- If female of child bearing age must use effective birth control.

Exclusion Criteria:

- Unwilling or unable to comply with study requirements

- Renal impairment (serum creatinine > 1.5 mg/dL)

- If maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1

- Patients who have had intolerable side effects to QTP, Li, Div, or LTG

- Patients whose clinical status requires inpatient care

- Drug/alcohol dependence within the past 30 days

- Pregnancy as determined by serum pregnancy test or breastfeeding

- History of poor response to Li at a serum Li of = 0.5 mEq/L (milliequivalents per Liter) or Div at a serum level of = 45 mg/dL for at least 2 weeks.

Study Design


Intervention

Drug:
Lithium
Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of =0.5mEq/L (milliequivalents per liter).
Divalproex
DV will be dosed to attain DV levels of =45mg/L.
Lamotrigine
LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
Quetiapine
QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.

Locations

Country Name City State
United States Case Western Reserve University Cleveland Ohio
United States University of Texas Health Science Center San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center at San Antonio National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bipolar Inventory of Symptoms Scale (BISS) The BISS uses a structured interview to assess the full spectrum of symptoms associated with all primary clinical states in bipolar disorder, yielding a total severity, a depression, a mania, as well as dimensional scale scores. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:
0 Not at all
Slight
Mild
Moderate
Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period. The mean score is calculated from the total score, giving an overall score out of 4, where 0 is slight and 4 is the most severe symptoms. A negative score indicated an improvement from baseline to 26 weeks.
Change from Baseline to 26 weeks
Secondary Global Assessment of Functioning The Clinical Global Impression-Severity Scale (CGI-S) is used to assess global illness severity
The CGI-S score change is measured from baseline to 26 weeks and is rated on a 7-point scale. The scale is read as follows:
very much improved since the initiation of treatment
much improved
minimally improved
no change from baseline (the initiation of treatment)
minimally worse
much worse
very much worse since the initiation of treatment The score is calculated as a mean of all items, where 1 indicates improvement from inititation of visit, and 7 indicates the condition to be much worse since the inititation of treatment. A negative score indicates a change from worse to better.
Change from Baseline to 26 weeks
Secondary Baseline Randomization Percentage of Bipolar Types Percentages of Type I and Type II Bipolar Disorder included in Randomization groups Baseline
Secondary Demographic in Randomization 1 Group Baseline demographic percentages of subject randomized to either Divalproex or Lithium at the first randomization Baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Withdrawn NCT01495156 - Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Phase 4
Completed NCT00982020 - Study in Adolescents With Schizophrenia or Bipolar Disorder Phase 4
Completed NCT00746343 - Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study N/A
Completed NCT00177463 - L-Carnosine for Bipolar I Disorder N/A
Completed NCT03257865 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Phase 3
Completed NCT03259555 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Phase 3
Not yet recruiting NCT06433635 - Sequential Multiple Assignment Randomized Trial for Bipolar Depression Phase 4
Completed NCT04127058 - Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia Phase 1
Recruiting NCT05977023 - NMDA Receptor Modulation for the Treatment of Bipolar I Disorder Phase 2
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT03287869 - A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Phase 3
Enrolling by invitation NCT04987229 - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Phase 3
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Completed NCT00232414 - A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder Phase 3
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Recruiting NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Phase 2
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3